OliX Pharmaceuticals, Inc. 226950
KRX · South Korea · Health Technology
KRW 116,900.00+14,400.00 (+14.05%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SEOUL, South Korea, July 30, 2026--New data highlight OLX501A’s potential to drive selective fat reduction, supporting its development as a next-generation RNAi-based obesity therapy.
SEOUL, South Korea, June 04, 2026--OliX, an RNAi developer, secures a KRW 110 billion biotech investment from BOLD and Weiss Asset Management LP.
Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA compatibility, CNS delivery efficiency, and biodistributionCollaboration underscores Vect-Horus’ leadership in blood-brain barrier technologyCNS as the next growth engine: Accelerating OliX 2.0 strategy MARSEILLE, France, and SEOUL, South Korea, Feb. 3, 2026 -- Vect-Horus, a France-based biotechnology company, and OliX Pharmaceuticals, Inc. (KOSDAQ: 226
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.